Caribou announces positive long-term follow-up from ANTLER Phase 1 of CB-010

Caribou Biosciences, Inc.

Positive long-term follow-up results from dose escalation portion of ANTLER Phase 1 trial.
CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for relapsed/refractory B-NHL.
Results announced July 13, 2023; this 8-K/A corrects an XBRL date error on the cover page.

item 8.01 item 9.01

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.